Timothy S Pardee

List of Publications by Year
in descending order

67 papers	3,051 citations	236612 25 h-index	161609 54 g-index
68 all docs	68 docs citations	68 times ranked	4597 citing authors

#	Article	IF	Citations
1	Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia. Nature Communications, 2022, 13, 1673.	5.8	13
2	Adenosine Monophosphate Activated Protein Kinase (AMPK) enhances chemotherapy response in Acute Myeloid Leukemia (AML). Cancer Letters, 2022, 535, 215659.	3.2	2
3	Tailoring a physical activity intervention to older adults receiving intensive chemotherapy for acute myeloid leukemia (AML): One size does not fit all. Journal of Geriatric Oncology, 2022, 13, 511-515.	0.5	1
4	Efficacy of 10-day decitabine in acute myeloid leukemia. Leukemia Research, 2021, 103, 106524.	0.4	7
5	A symptom-adapted physical activity intervention during induction chemotherapy for older adults with acute myeloid leukemia (AML) to maintain physical function.. Journal of Clinical Oncology, 2021, 39, 12009-12009.	0.8	1
6	A multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin with or without CPI-613 as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-04).. Journal of Clinical Oncology, 2021, 39, TPS4158-TPS4158.	0.8	0
7	Re-induction therapy in adult patients with acute myeloid leukemia with â‰20 % blasts: A retrospective cohort study. Leukemia Research, 2021, 111, 106731.	0.4	2
8	Inflammatory biomarkers, geriatric assessment, and treatment outcomes in acute myeloid leukemia. Journal of Geriatric Oncology, 2020, 11, 410-416.	0.5	16
9	Geriatric assessment and survival among older adults receiving postremission therapy for acute myeloid leukemia. Blood, 2020, 136, 2715-2719.	0.6	29
10	Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. Leukemia, 2020, 34, 2903-2913.	3.3	38
11	The Novel Phospholipid Mimetic KPC34 Is Highly Active Against Acute Myeloid Leukemia with Activated Protein Kinase C. Translational Oncology, 2020, 13, 100780.	1.7	0
12	Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. Blood Advances, 2020, 4, 696-705.	2.5	44
13	The prognostic value of standardized phase angle in adults with acute leukemia: A prospective study. Cancer Medicine, 2020, 9, 2403-2413.	1.3	12
14	Acute Myeloid Leukemia in Older Adults. , 2020, , 501-520.		1
15	A single-arm, open-label, phase I study of CPI-613 (Devimistat) in combination with gemcitabine and nab-paclitaxel for patients with locally advanced or metastatic pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2020, 38, 4635-4635.	0.8	4
16	Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. New England Journal of Medicine, 2019, 381, 1728-1740.	13.9	796
17	A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas. Future Oncology, 2019, 15, 3189-3196.	1.1	64
18	Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III study. Future Oncology, 2019, 15, 3197-3208.	1.1	23

#	Article	IF	Citations
19	Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity. Cell Metabolism, 2019, 29, 1217-1231.e7.	7.2	75
20	Association between glycemic control, age, and outcomes among intensively treated patients with acute myeloid leukemia. Supportive Care in Cancer, 2019, 27, 2877-2884.	1.0	7
21	Acute Myeloid Leukemia in Older Adults. , 2019, , 1-20.		0
22	A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. Clinical Cancer Research, 2018, 24, 2060-2073.	3.2	72
23	Mitochondria in cancer metabolism, an organelle whose time has come?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1870, 96-102.	3.3	42
24	Therapeutic Manipulation of Cancer Cell Metabolism with the Mitochondrial Metabolism Inhibitor Cpi-613 in Addition to Chemotherapy Abrogates the Adverse Prognostic Effect of Age in Relapsed and Refractory AML. Blood, 2018, 132, 1355-1355.	0.6	3
25	Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncology, The, 2017, 18, 770-778.	5.1	167
26	Outcomes and changes in code status of patients with acute myeloid leukemia undergoing induction chemotherapy who were transferred to the intensive care unit. Leukemia Research, 2017, 62, 51-55.	0.4	10
27	The novel phospholipid mimetic KPC34 is highly active against preclinical models of Philadelphia chromosome positive acute lymphoblastic leukemia. PLoS ONE, 2017, 12, e0179798.	1.1	3
28	Association between glycemic control, age, and outcomes among intensively treated patients with acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2017, 35, 10043-10043.	0.8	0
29	A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma. PLoS ONE, 2016, 11, e0164244.	1.1	43
30	Effect of Intensive Chemotherapy on Physical, Cognitive, and Emotional Health of Older Adults with Acute Myeloid Leukemia. Journal of the American Geriatrics Society, 2016, 64, 1988-1995.	1.3	72
31	The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence. Future Oncology, 2016, 12, 2009-2020.	1.1	33
32	Improving nucleoside analogs via lipid conjugation: Is fatter any better?. Critical Reviews in Oncology/Hematology, 2016, 100, 46-56.	2.0	12
33	Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML). Journal of Geriatric Oncology, 2016, 7, 24-31.	0.5	48
34	TCA Cycle Inhibition By Cpi-613 Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML). Blood, 2016, 128, 4062-4062.	0.6	5
35	Pilot study of first-in-class antimitochondrial metabolism agent, CPI-613, as salvage monotherapy for small cell lung cancer.. Journal of Clinical Oncology, 2016, 34, e20100-e20100.	0.8	0
36	Retrospective analysis of nadir bone marrow biopsies in predicting need for re-induction therapy in adult acute myeloid leukemia.. Journal of Clinical Oncology, 2016, 34, e18509-e18509.	0.8	0

#	Article	IF	Citations
37	Clinicopathological analysis of near-tetraploidy/tetraploidy acute myeloid leukaemia. Journal of Clinical Pathology, 2015, 68, 236-240.	1.0	15
38	High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly. Leukemia Research, 2015, 39, 945-949.	0.4	21
39	Thymineless death in F10-treated AML cells occurs via lipid raft depletion and Fas/FasL co-localization in the plasma membrane with activation of the extrinsic apoptotic pathway. Leukemia Research, 2015, 39, 229-235.	0.4	16
40	Feasibility of a Symptom-Adapted Physical Activity Intervention during Induction Chemotherapy for Older Adults with Acute Myeloid Leukemia (AML). Blood, 2015, 126, 2102-2102.	0.6	1
41	The Mitochondrial Metabolism Inhibitor Cpi-613 in Combination with High Dose Ara-C (HDAC) and Mitoxantrone Is Highly Active in Poor Risk Relapsed or Refractory Acute Myeloid Leukemia (AML). Blood, 2015, 126, 2556-2556.	0.6	0
42	Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). Annals of Hematology, 2014, 93, 47-55.	0.8	54
43	Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Adults. Journal of Clinical Oncology, 2014, 32, 2541-2552.	0.8	132
44	A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies. Clinical Cancer Research, 2014, 20, 5255-5264.	3.2	82
45	The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML). Leukemia Research, 2014, 38, 1184-1190.	0.4	68
46	Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance). Blood, 2014, 124, 8-8.	0.6	31
47	The Efficacy of the Ribonucleotide Reductase Inhibitor Didox in Preclinical Models of AML. PLoS ONE, 2014, 9, e112619.	1.1	8
48	The poison oligonucleotide F10 is highly effective against acute lymphoblastic leukemia while sparing normal hematopoietic cells. Oncotarget, 2014, 5, 4170-4179.	0.8	17
49	Subcutaneous panniculitis-like T cell lymphoma with mesenteric involvement. Journal of Hematopathology, 2013, 6, 155-159.	0.2	5
50	Animal models of leukemia: any closer to the real thing?. Cancer and Metastasis Reviews, 2013, 32, 63-76.	2.7	40
51	Non-homologous end joining mediated DNA repair is impaired in the NUP98-HOXD13 mouse model for myelodysplastic syndrome. Leukemia Research, 2013, 37, 112-116.	0.4	13
52	Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10] anti-leukemic activity. Experimental Hematology, 2013, 41, 180-188.e4.	0.2	13
53	Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood, 2013, 121, 4287-4294.	0.6	348
54	High Dose Cytarabine, Mitoxantrone and L-Asparaginase (HAMA) Salvage For Relapsed Or Refractory Acute Myeloid Leukemia (AML) In The Elderly. Blood, 2013, 122, 2700-2700.	0.6	2

#	Article	IF	Citations
55	Adding The KIT Inhibitor Dasatinib (DAS) To Standard Induction and Consolidation Therapy For Newly Diagnosed Patients (pts) With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Initial Results Of The CALGB 10801 (Alliance) Study. Blood, 2013, 122, 357-357.	0.6	20
56	Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity. Blood, 2012, 119, 3561-3570.	0.6	37
57	Overexpression of MN1 Confers Resistance to Chemotherapy, Accelerates Leukemia Onset, and Suppresses p53 and Bim Induction. PLoS ONE, 2012, 7, e43185.	1.1	13
58	Thymidylate Synthase Inhibition with the Novel Fluoropyrimidine FdUMP[10] Is Highly Effective Against Acute Lymphoblastic Leukemia. Blood, 2012, 120, 1505-1505.	0.6	0
59	The Feasibility of Inpatient Geriatric Assessment for Older Adults Receiving Induction Chemotherapy for Acute Myelogenous Leukemia. Journal of the American Geriatrics Society, 2011, 59, 1837-1846.	1.3	117
60	Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner. Experimental Hematology, 2011, 39, 473-485.e4.	0.2	27
61	Altered Lipid and Mitochondrial Metabolism Are Viable Targets in Acute Leukemia,. Blood, 2011, 118, 3618-3618.	0.6	3
62	Over Expression of MN1 Accelerates Leukemia Onset and Confers Resistance to Chemotherapy by Suppression of p53 and Bim. Blood, 2011, 118, 2501-2501.	0.6	0
63	Unique Dual Targeting of Thymidylate Synthase and Topoisomerase1 by FdUMP[10] Results in High Efficacy Against AML and Low Toxicity. Blood, 2011, 118, 2584-2584.	0.6	0
64	Mouse models of human AML accurately predict chemotherapy response. Genes and Development, 2009, 23, 877-889.	2.7	235
65	The Flt3 ITD Accelerates An Already Established Myeloid Leukemia and Alters Chemotherapy Response In Vitro and In Vivo in a p53 Dependent Manner.. Blood, 2009, 114, 1719-1719.	0.6	0
66	Yeast and Human RNA Polymerase II Elongation Complexes: Evidence for Functional Differences and Postinitiation Recruitment of Factors. Eukaryotic Cell, 2003, 2, 318-327.	3.4	6
67	The N-terminal Region of Yeast TFIIB Contains Two Adjacent Functional Domains Involved in Stable RNA Polymerase II Binding and Transcription Start Site Selection. Journal of Biological Chemistry, 1998, 273, 17859-17864.	1.6	82